Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rik Schrijvers

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Expert Opinion on Pharmacotherapy|April 9, 2013
Etravirine for the treatment of HIV/AIDSRik Schrijvers
The Lancet. Infectious Diseases|February 22, 2015
Five-drug antiretroviral therapy for primary HIV infection?Zeger Debyser, Rik Schrijvers
Lancet (London, England)|July 4, 2012
Quad's in it for antiretroviral therapy?Rik Schrijvers, Zeger Debyser
The Journal of Allergy and Clinical Immunology|June 26, 2025
The 2024 anaphylaxis consensus report: A new jacket for a known disease to boost awareness and standardizationDominique Bullens, Rik Schrijvers
The Lancet. Infectious Diseases|June 9, 2014
Switching STRATEGIES in HIV treatmentRik Schrijvers, Zeger Debyser
Expert Opinion on Pharmacotherapy|August 2, 2012
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDFRik Schrijvers, Zeger Debyser
The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2024
A New Year, A New Era in Drug Hypersensitivity-Looking Beyond the Classical ParadigmsRik Schrijvers, Elizabeth J Phillips
The Journal of Allergy and Clinical Immunology|November 11, 2015
Subgroups in cephalosporin allergy, making a patient-tailored approach redundant?Sebastiaan Tuyls, Christine Breynaert, Rik Schrijvers
The Lancet. Infectious Diseases|October 22, 2011
Elvitegravir: a once daily alternative to raltegravirBelete Ayele Desimmie, Rik Schrijvers, Zeger Debyser
Lancet (London, England)|July 19, 2011
Rilpivirine: a step forward in tailored HIV treatmentRik Schrijvers, Belete Ayele Desimmie, Zeger Debyser
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Expert Opinion on Pharmacotherapy|April 9, 2013
Etravirine for the treatment of HIV/AIDSRik Schrijvers
The Lancet. Infectious Diseases|February 22, 2015
Five-drug antiretroviral therapy for primary HIV infection?Zeger Debyser, Rik Schrijvers
Lancet (London, England)|July 4, 2012
Quad's in it for antiretroviral therapy?Rik Schrijvers, Zeger Debyser
The Journal of Allergy and Clinical Immunology|June 26, 2025
The 2024 anaphylaxis consensus report: A new jacket for a known disease to boost awareness and standardizationDominique Bullens, Rik Schrijvers
The Lancet. Infectious Diseases|June 9, 2014
Switching STRATEGIES in HIV treatmentRik Schrijvers, Zeger Debyser
Expert Opinion on Pharmacotherapy|August 2, 2012
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDFRik Schrijvers, Zeger Debyser
The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2024
A New Year, A New Era in Drug Hypersensitivity-Looking Beyond the Classical ParadigmsRik Schrijvers, Elizabeth J Phillips
The Journal of Allergy and Clinical Immunology|November 11, 2015
Subgroups in cephalosporin allergy, making a patient-tailored approach redundant?Sebastiaan Tuyls, Christine Breynaert, Rik Schrijvers
The Lancet. Infectious Diseases|October 22, 2011
Elvitegravir: a once daily alternative to raltegravirBelete Ayele Desimmie, Rik Schrijvers, Zeger Debyser
Lancet (London, England)|July 19, 2011
Rilpivirine: a step forward in tailored HIV treatmentRik Schrijvers, Belete Ayele Desimmie, Zeger Debyser
Pageof 14